2025. First-Line Ipilimumab with Nivolumab versus Immune Checkpoint Inhibitors with Tyrosine Kinase Inhibitors in Patients with Intermediate- or Poor-Risk Metastatic Clear Cell Renal Cell Carcinoma. Journal of Kidney Cancer. 12, 2 (Apr. 2025), 27–36. DOI:https://doi.org/10.15586/jkcvhl.v12i2.387.